•  
  •  
 

Subject Area

Ophthalmology

Article Type

Original Study

Abstract

Objective To study the benefit of addition of oral fenofibrate to the standard management of diabetic macular edema (DME) regarding central macular thickness (CMT) and visual function. Background DME is the commonest cause of vision loss in diabetes. Systemic therapy for DME largely meant control of diabetes, hypertension, and lipid levels. A revival in the use of systemic medication for a local condition caused by a systemic disease has occurred recently with hypolipidemic drugs, namely, atorvastatin and fenofibrate. Patients and methods Our study was a randomized controlled trial. It included 100 eyes of patients with type-2 diabetes complicated with DME. Patients were randomized into two groups: treatment group (oral fenofibrate) and control group (receiving placebo). Both groups underwent treatment of DME as per the standard treatment protocol of our hospital, including intravitreal injections and grid laser. Patients were followed up after 3 and 6 months to note the CMT and visual acuity. Results There was a significant lower mean value of CMT with higher mean value of percent reduction (19.22 vs. 13.256%) and higher mean value of visual acuity in fenofibrate group than the control group after 6 months of treatment. Conclusions Adding of fenofibrate (dose of 160 mg/day for 6 months) to standard protocols of DME treatment has beneficial effect on percent reduction in CMT and visual acuity.

Download

Share

COinS